drugset / Trial / NCT06081062
Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
Evaluate the safety and efficacy of Fabagal® developed by ISU ABXIS Co., Ltd., which has similar efficacy to active comparator (Agalsidase beta).
Timeline
- Start
- 2023-04-14
- Primary completion
- 2025-06
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | agalsidase beta | Protein / enzyme biologic | 1 mg/kg | — |